Date	Event	Description
29 March 2017	New search has been performed	New literature search run
29 March 2017	New citation required and conclusions have changed	Scope broadened to encompass all Anti IL 5 therapies (reslizumab and benralizumab), rather than mepolizumab alone Review substantively redrafted Inclusion criteria applied more strictly resulting in exclusion of five (out of eight) mepolizumab studies Search updated leading to the inclusion of 10 new studies (one mepolizumab, four reslizumab and five benralizumab) Groups on doses of the trial medications that are not clinically relevant (e.g. 10 times higher or lower) have been excluded from the analysis Outcomes revised to focus on validated symptom scores, only a pre‐bronchodilator measure of lung function, subgroups for eosinophilia or otherwise New author team